Alzheimer’s Early Detection Act of 2026

The Alzheimer's Early Detection Act of 2026 requires private health insurance plans and Medicaid programs to cover specific tests that detect biological markers for Alzheimer's disease. These tests, which can be performed on blood or tissue samples, are intended to help with early detection, diagnosis, and treatment management of the condition. The law mandates that insurers treat these tests like other standard medical benefits, meaning patients cannot face higher costs, separate waiting periods, or step therapy hurdles specifically for this care. Additionally, the bill requires insurance companies to approve requests for these tests within 72 hours and directs the National Institutes of Health to study the value of such testing over three years.